Loading...
26 famotidine COVID-19 controlled studies, 4 RCTs
https://c19early.org/fmmeta.html
0
0.25
0.5
0.75
1
1.25
1.5
1.75
2+
Brennan (DB RCT) 48%
0.52 [0.20-1.32]
no recov.
5/27
10/28
Improvement, RR [CI] Treatment Control Brennan (DB RCT) 43%
0.57 [0.21-1.55]
no recov.
4/19
10/27
Brennan (DB RCT) 28%
0.72 [0.56-0.92]
recov. time
27 (n)
28 (n)
Shoaibi -3%
1.03 [0.89-1.18]
death
1,816 (n)
26,820 (n)
Shoaibi -3%
1.03 [0.92-1.15]
death/ICU
1,816 (n)
26,820 (n)
Zhou (PSM) -81%
1.81 [1.28-2.58]
severe case
72/519
198/2,595
Yeramaneni -59%
1.59 [0.94-2.71]
death
410 (n)
746 (n)
Mura (PSM) 21%
0.79 [0.65-0.96]
death
563 (n)
563 (n)
Mura (PSM) 37%
0.63 [0.47-0.83]
death
305 (n)
305 (n)
Samim.. (SB RCT) 33%
0.67 [0.45-0.98]
hosp. time
10 (n)
10 (n)
Samim.. (SB RCT) 0%
1.00 [0.42-2.40]
no recov.
5/10
5/10
Samim.. (SB RCT) 50%
0.50 [0.17-1.46]
no recov.
3/10
6/10
Elhadi (ICU) 7%
0.93 [0.73-1.17]
death
34/60
247/405
ICU patients
Taşdemir 45%
0.55 [0.20-1.55]
death
5/85
10/94
OT1
Taşdemir 37%
0.63 [0.28-1.43]
ICU
8/85
14/94
OT1
Taşdemir 18%
0.82 [0.72-0.93]
hosp. time
85 (n)
94 (n)
OT1
Taşdemir 20%
0.80 [0.65-0.99]
recov. time
85 (n)
94 (n)
OT1
Kuno (PSM) 0%
1.00 [0.86-1.17]
death
1,593 (n)
7,972 (n)
Stolow -519%
6.19 [2.10-18.3]
death
137 (n)
352 (n)
Stolow -2390%
24.90 [3.70-168]
ICU
137 (n)
352 (n)
Wagner 70%
0.30 [0.20-0.44]
death
638 (n)
819 (n)
Pahwani (RCT) 11%
0.89 [0.36-2.20]
death
8/89
9/89
Pahwani (RCT) 12%
0.88 [0.53-1.45]
ventilation
21/89
24/89
Pahwani (RCT) 10%
0.90 [0.51-1.58]
ICU
18/89
20/89
Pahwani (RCT) 17%
0.83 [0.79-0.89]
hosp. time
89 (n)
89 (n)
Pahwani (RCT) 10%
0.90 [0.85-0.96]
recov. time
89 (n)
89 (n)
Siraj 36%
0.64 [0.48-0.83]
death
183/711
122/289
Zangeneh (ICU) 39%
0.61 [0.42-0.90]
death
n/a
n/a
ICU patients
Chowdhury (RCT) 16%
0.84 [0.54-1.31]
death
26/104
31/104
ICU patients
Chowdhury (RCT) 9%
0.91 [0.75-1.10]
ICU
78 (n)
73 (n)
ICU patients
Chowdhury (RCT) 33%
0.67 [0.58-0.78]
no improv.
78 (n)
73 (n)
ICU patients
Chowdhury (RCT) 7%
0.93 [0.84-1.03]
recov. time
78 (n)
73 (n)
ICU patients
Chowdhury (RCT) 17%
0.83 [0.72-0.96]
hosp. time
78 (n)
73 (n)
ICU patients
Chowdhury (RCT) 13%
0.87 [0.80-0.95]
viral time
78 (n)
73 (n)
ICU patients
Freedberg (PSM) 57%
0.43 [0.21-0.86]
death/int.
8/84
332/1,536
Mather (PSM) 61%
0.39 [0.20-0.74]
death
83 (n)
689 (n)
Mather (PSM) 50%
0.49 [0.31-0.79]
death/int.
83 (n)
689 (n)
Balouch 22%
0.78 [0.36-1.51]
symp. case
18/80
49/227
Balouch 37%
0.63 [0.26-1.54]
recov. time
80 (n)
227 (n)
Yeramaneni 51%
0.49 [0.16-1.52]
death
351 (n)
6,807 (n)
Cheung -34%
1.34 [0.24-6.06]
severe case
23 (n)
929 (n)
Fung 0%
1.00 [0.96-1.04]
death
population-based cohort
Fung 6%
0.94 [0.91-0.97]
hosp.
population-based cohort
Fung -12%
1.12 [1.10-1.15]
cases
population-based cohort
Razjouyan 27%
0.73 [0.59-0.92]
death
93 (n)
9,981 (n)
Wallace -11%
1.11 [0.89-1.35]
death
98/423
1,436/7,521
MacFadden 7%
0.93 [0.84-1.03]
cases
n/a
n/a
Loucera 18%
0.82 [0.59-1.15]
death
207 (n)
15,761 (n)
Kim 36%
0.64 [0.51-0.80]
cases
105/5,594
480/15,432
Famotidine COVID-19 outcomes c19 early.org/fm May 20231 OT: comparison with other treatment Favors famotidine
Favors control
Please send us corrections, updates, or comments. Vaccines and
treatments are complementary. All practical, effective, and safe means should
be used based on risk/benefit analysis. No treatment, vaccine, or intervention
is 100% available and effective for all current and future variants. We do not
provide medical advice. Before taking any medication, consult a qualified
physician who can provide personalized advice and details of risks and
benefits based on your medical history and situation.
FLCCC and
WCH
provide treatment protocols.
Submit
